Loading…
Employees: 33
Size SanBio (4592.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $393M, the 1193rd largest of 1,379 Japan companies the cockpit tracks. Shares closed at ¥794 on 6 Nov 2026.
Performance Over six months the shares fell 57.6%, against -14.5% for the median peer and +1.8% for the Japan market (cap-weighted) — 3rd lowest of 21 in its peer set.
Next results Next results expected around 10 Dec 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥0 | ¥0 | ¥0 | ¥0 | ¥0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -¥31.5M | -¥8.05M | -¥9.37M | -¥14.5M | -¥24.6M |
| EBITDA | -¥3.79B | -¥3.79B | -¥3.51B | -¥4.53B | -¥7.87B |
| Net income | -¥3.64B | -¥3.84B | -¥2.88B | -¥2.64B | -¥5.56B |
| Free cash flow | n/a | -¥3.84B | -¥3.62B | -¥4.79B | -¥7.46B |
| Capital expenditure | n/a | ¥32.8M | ¥4.89M | ¥55.0M | ¥8.00M |
| Total debt | ¥1.13B | ¥1.24B | ¥397M | ¥665M | ¥933M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 4592.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -20.8% | -9.6% | 4th lowest of 21 |
| 6-month return | -57.6% | -14.5% | 3rd lowest of 21 |
| Distance from 52-week high | -72.9% | -34.9% | 3rd lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| SanBio 4592.T | Japan | $393M | -58% | n/a | n/a | n/a | n/a | n/a |
| Heartseed 219A.T | Japan | $393M | +52% | +197% | 9% | 21.4× | 50.0% | +73.2% |
| Tiansheng Pharmaceutical 002872.SZ | China | $392M | +15% | -1% | -13% | 5.2× | 23.2% | -15.7% |
| Zota Health Care ZOTA.NS | India | $395M | -6% | +69% | -16% | 5.8× | n/a | n/a |
| iX Biopharma 42C.SI | Singapore | $386M | +10% | -12% | -140% | 70.7× | n/a | n/a |
| Tuoxin Pharmaceutical 301089.SZ | China | $400M | -22% | +17% | -20% | 5.8× | n/a | n/a |
| Kwality Pharmaceuticals KPL.NS | India | $401M | +111% | +38% | 21% | 6.8× | n/a | n/a |
| Hyundai Bioscience 048410.KS | South Korea | $401M | -58% | +78% | -580% | 158.2× | n/a | n/a |
| Guangdong Lifestrong Pharmacy 301111.SZ | China | $401M | -16% | +7% | -2% | 7.9× | n/a | n/a |
| MapLight Therapeutics MPLT | United States | $385M | -75% | n/a | n/a | n/a | n/a | n/a |
| JW Pharmaceutical 001060.KS | South Korea | $402M | -28% | +10% | 14% | 0.7× | -16.9% | +7.2% |
| JCR Pharmaceuticals 4552.T | Japan | $383M | -11% | +3% | -14% | 2.9× | n/a | n/a |
| Shandong Sinobioway Biomedicine 002581.SZ | China | $404M | -40% | +91% | -65% | 7.8× | n/a | n/a |
| Hansa Biopharma HNSA.ST | Sweden | $410M | +39% | -4% | -304% | 23.7× | n/a | n/a |
| Guizhou Yibai Pharmaceutical 600594.SS | China | $376M | -21% | -26% | -15% | 2.0× | 9.0% | -11.3% |
| Shaanxi Panlong Pharmaceutical 002864.SZ | China | $411M | -13% | -9% | 9% | 1.6× | -0.4% | +11.2% |
| Rezolute RZLT | United States | $375M | +21% | n/a | n/a | n/a | n/a | n/a |
| Anhui Sunhere Pharmaceutical Excipients 300452.SZ | China | $412M | -16% | +9% | 19% | 2.4× | -4.5% | +12.1% |
| Unichem Laboratories UNICHEMLAB.NS | India | $373M | +28% | +9% | 5% | 1.5× | n/a | n/a |
| Jiangxi Synergy Pharmaceutical 300636.SZ | China | $414M | -16% | -2% | 3% | 3.5× | n/a | n/a |
| Chongqing Hifuture Information Technology 002168.SZ | China | $372M | -23% | +2% | -6% | 8.3× | 16.3% | -14.0% |